Second Cancer Incidence in CLL Patients Receiving BTK Inhibitors

[1]  J. Byrd,et al.  Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial , 2020, The Lancet.

[2]  J. Byrd,et al.  Acalabrutinib Plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia. , 2020, Cancer discovery.

[3]  S. Shumack,et al.  Chronic lymphocytic leukemia, skin and other second cancers , 2019, Leukemia & lymphoma.

[4]  J. Woyach,et al.  Targeting BTK in CLL: Beyond Ibrutinib , 2019, Current Hematologic Malignancy Reports.

[5]  J. Vose,et al.  Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). , 2019, Journal of Clinical Oncology.

[6]  J. Byrd,et al.  Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies , 2019, Leukemia.

[7]  R. Houlston,et al.  Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia , 2019, British journal of haematology.

[8]  A. López-Guillermo,et al.  Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. , 2019, The Lancet. Haematology.

[9]  D. Armstrong-James,et al.  Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. , 2018, Blood.

[10]  H. Uno,et al.  Low T-cell subsets prior to development of virus-associated cancer in HIV-seronegative men who have sex with men , 2018, Cancer Causes & Control.

[11]  G. Redelman-Sidi,et al.  Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  L. Ysebaert,et al.  Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. , 2018, Blood.

[13]  Jeffrey A Jones,et al.  Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. , 2018, Blood.

[14]  D. Kontoyiannis,et al.  Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Asgari,et al.  Association of Multiple Primary Skin Cancers With Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load , 2017, JAMA dermatology.

[16]  D. Rimland,et al.  Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. , 2017, The lancet. HIV.

[17]  P. Sharma,et al.  Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial , 2016 .

[18]  A. Wiestner,et al.  Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. , 2016, Blood.

[19]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[20]  M. Hallek,et al.  Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL , 2016, Leukemia.

[21]  G. Marti,et al.  Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. , 2015, Blood.

[22]  P. Moss,et al.  Perturbation of the normal immune system in patients with CLL. , 2015, Blood.

[23]  Z. Estrov,et al.  Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes , 2015, Leukemia & lymphoma.

[24]  Jeffrey A Jones,et al.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. , 2015, Blood.

[25]  B. Alexander,et al.  Relationship between ambient ultraviolet radiation and non‐Hodgkin lymphoma subtypes: A U.S. population‐based study of racial and ethnic groups , 2015, International journal of cancer.

[26]  V. Lougaris,et al.  Bruton tyrosine kinase mediates TLR9-dependent human dendritic cell activation. , 2014, The Journal of allergy and clinical immunology.

[27]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[28]  P. Baade,et al.  Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study , 2011, British Journal of Cancer.

[29]  P. Reiss,et al.  Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  L. Bullinger,et al.  Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. , 2011, Blood.

[31]  M. Tucker,et al.  Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Dasanu.  Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice , 2008 .

[33]  M. Falster,et al.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.

[34]  C. Pipper,et al.  Risk of second cancer after chronic lymphocytic leukemia , 2007, International journal of cancer.

[35]  J. Kaldor,et al.  Cancer incidence before and after kidney transplantation. , 2006, JAMA.

[36]  H. Kantarjian,et al.  Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  E. Ma,et al.  Therapy‐related acute myeloid leukemia after single‐agent treatment with fludarabine for chronic lymphocytic leukemia , 2005, American journal of hematology.

[38]  Fred R. Dee,et al.  Cigarette Smoking and Risk of Non-Hodgkin Lymphoma: A Pooled Analysis from the International Lymphoma Epidemiology Consortium (InterLymph) , 2005, Cancer Epidemiology Biomarkers & Prevention.

[39]  S. Schichman,et al.  Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) have a Markedly Increased Rate of Second Malignancy, which is the Most Common Cause of Death , 2004, Leukemia & lymphoma.

[40]  K. Sułek,et al.  Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. , 2004, European journal of cancer.

[41]  Lois Shepherd,et al.  Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Greene,et al.  Solid tumors after chronic lymphocytic leukemia. , 2001, Blood.

[43]  K. Nakachi,et al.  Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population , 2000, The Lancet.

[44]  M. Schlesinger,et al.  The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. , 1996, Leukemia.

[45]  H. Storm,et al.  Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemia , 1994, European journal of haematology.

[46]  B. Hankey,et al.  Second cancers in patients with chronic lymphocytic leukemia. , 1992, Journal of the National Cancer Institute.

[47]  A. Durántez,et al.  Clinical signification of natural killer activity in B‐cell chronic lymphocytic leukemia , 1987, European journal of haematology.

[48]  N. Kay,et al.  Abnormal T cell function in early‐stage chronic lymphocytic leukemia (CLL) patients , 1986, American journal of hematology.

[49]  R. Hoover,et al.  Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism. , 1978, Journal of the National Cancer Institute.

[50]  B. Weinerman,et al.  Subsequent neoplasia in chronic lymphocytic leukemia. , 1975, JAMA.

[51]  T. Shanafelt,et al.  Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia. , 2014, Journal of oncology practice.

[52]  Hardeo Sahai,et al.  Confidence Intervals for the Mean of a Poisson Distribution: A Review , 1993 .